Raub Brock Capital Management LP Lowers Position in Zoetis Inc. $ZTS

Raub Brock Capital Management LP lessened its stake in Zoetis Inc. (NYSE:ZTS) by 5.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 89,592 shares of the company’s stock after selling 5,409 shares during the quarter. Zoetis makes up about 2.5% of Raub Brock Capital Management LP’s holdings, making the stock its 19th largest position. Raub Brock Capital Management LP’s holdings in Zoetis were worth $11,272,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Mn Services Vermogensbeheer B.V. grew its stake in shares of Zoetis by 2.9% in the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 173,669 shares of the company’s stock worth $21,851,000 after acquiring an additional 4,966 shares in the last quarter. Vantage Wealth lifted its position in shares of Zoetis by 20.4% during the fourth quarter. Vantage Wealth now owns 130,555 shares of the company’s stock valued at $16,426,000 after purchasing an additional 22,085 shares in the last quarter. Spire Wealth Management boosted its holdings in Zoetis by 5.9% during the fourth quarter. Spire Wealth Management now owns 5,317 shares of the company’s stock worth $669,000 after purchasing an additional 294 shares during the last quarter. Cascade Investment Advisors Inc. purchased a new position in Zoetis during the fourth quarter worth about $1,499,000. Finally, Baron Wealth Management LLC grew its position in Zoetis by 71.4% in the 4th quarter. Baron Wealth Management LLC now owns 2,965 shares of the company’s stock worth $373,000 after purchasing an additional 1,235 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $116.41 on Tuesday. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. The firm has a market cap of $49.14 billion, a price-to-earnings ratio of 19.34, a P/E/G ratio of 1.73 and a beta of 0.95. Zoetis Inc. has a 52 week low of $113.29 and a 52 week high of $172.23. The firm’s 50-day simple moving average is $123.23 and its two-hundred day simple moving average is $128.79.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. During the same period in the prior year, the firm earned $1.40 EPS. The company’s revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.22%.

Wall Street Analyst Weigh In

Several equities research analysts have commented on ZTS shares. BTIG Research reiterated a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a research note on Thursday, February 26th. Piper Sandler reaffirmed a “neutral” rating and issued a $135.00 target price (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday. UBS Group set a $136.00 price target on Zoetis in a report on Thursday, January 29th. Finally, Bank of America boosted their price objective on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, February 13th. Six analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.